Paper

Human genetic diversity modifies therapeutic gene editing off-target potential

Zeng, Jing, Cancellieri, Samuele, Pinello, Luca, Masillo, Francesco, Katta, Varun, Bauer, Daniel Evan, Nguyen, Amy, Lin, Linda Yingqi, Giugno, Rosalba, Tsai, Shengdar, Ciuculescu, Felicia, Armant, Myriam, Bombieri, Nicola

2021

Overview

CRISPR gene editing holds great promise to modify somatic genomes to ameliorate disease. In silico prediction of homologous sites coupled with biochemical evaluation of possible genomic off-targets may predict genotoxicity risk of individual gene editing reagents. However, standard computational and biochemical methods focus on reference genomes and do not consider the impact of genetic diversity on off-target potential. Here we developed a web application called CRISPRme that explicitly and efficiently integrates human genetic variant datasets with orthogonal genomic annotations to predict and prioritize off-target sites at scale. The method considers both single-nucleotide variants (SNVs) and indels, accounts for bona fide haplotypes, accepts spacer:protospacer mismatches and bulges, and is suitable for personal genome analyses. We tested the tool with a guide RNA (gRNA) targeting the BCL11A erythroid enhancer that has shown therapeutic promise in clinical trials for sickle cell disease (SCD) and β-thalassemia. We find that the top predicted off-target site is produced by a non-reference allele common in African-ancestry populations (rs114518452, minor allele frequency (MAF)=4.5%) that introduces a protospacer adjacent motif (PAM) for SpCas9. We validate that SpCas9 generates indels (~9.6% frequency) and chr2 pericentric inversions in a strictly allele-specific manner in edited CD34+ hematopoietic stem/progenitor cells (HSPCs), although a high-fidelity Cas9 variant mitigates this off-target. This report illustrates how genetic variation may modify the genomic outcomes of therapeutic gene editing and provides a simple tool for comprehensive off-target assessment. Competing Interest Statement L.P. has financial interests in Edilytics, Inc., Excelsior Genomics, and SeQure Dx, Inc. L.P.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Footnotes * http://crisprme.di.univr.it

• Publisher: Cold Spring Harbor Laboratory Press
• Subject: Alleles / CD34 antigen / Clinical trials / Computer applications / CRISPR / Gene frequency / Genetic diversity / Genomes / Genomics / Genotoxicity / gRNA / Haplotypes / Hematopoietic stem cells / Population genetics / Progenitor cells / Sickle cell disease / Thalassemia